Core Viewpoint - The animal health sector experienced a significant increase of 3.8% on January 5, with Haili Biological leading the gains, while the overall market indices also showed positive performance [1] Group 1: Market Performance - The Shanghai Composite Index closed at 4023.42, up by 1.38% [1] - The Shenzhen Component Index closed at 13828.63, up by 2.24% [1] Group 2: Individual Stock Performance - Haili Biological (603718) closed at 6.58, with a rise of 7.87% and a trading volume of 461,200 shares, amounting to a transaction value of 302 million yuan [1] - Biological Shares (600201) closed at 16.06, increasing by 6.57% with a trading volume of 553,300 shares, totaling 88.5 million yuan [1] - ST Green Health (002868) closed at 35.40, up by 5.01% with a trading volume of 14,600 shares, amounting to 5.124 million yuan [1] - Shunlian Biological (688098) closed at 9.29, increasing by 4.62% with a trading volume of 65,000 shares, totaling 60.117 million yuan [1] - Ruipu Biological (300119) closed at 19.53, up by 4.05% with a trading volume of 78,500 shares, amounting to 151 million yuan [1] - KQ Biological (688526) closed at 15.68, increasing by 2.75% with a trading volume of 29,900 shares, totaling 46.631 million yuan [1] - Huisheng Biological (300871) closed at 21.25, up by 2.51% with a trading volume of 61,500 shares, amounting to 129 million yuan [1] - Qudongli (920275) closed at 8.91, increasing by 2.30% with a trading volume of 10,300 shares, totaling 911,930 yuan [1] - Placo (603566) closed at 12.71, up by 2.25% with a trading volume of 36,700 shares, amounting to 46.3405 million yuan [1] - Jinhai Biological (002688) closed at 6.03, increasing by 1.34% with a trading volume of 105,100 shares, totaling 63.2745 million yuan [1] Group 3: Capital Flow Analysis - The animal health sector saw a net inflow of 77.0149 million yuan from main funds, while retail funds experienced a net outflow of 33.0955 million yuan [1] - The main funds' net inflow for Haili Biological was -54.2922 million yuan, with a net outflow from retail funds of -35.0631 million yuan [2] - Ruipu Biological had a net inflow of 15.0755 million yuan from main funds, while retail funds saw a net inflow of 555.73 thousand yuan [2] - Biological Shares had a net inflow of 1.5843 million yuan from main funds, with a net outflow from retail funds of -1529.42 thousand yuan [2]

Core Viewpoint - The article discusses the growth and development of Ruipai Pet, a national chain of pet medical institutions in China, founded by Li Shoujun, who transitioned from a state-owned enterprise to entrepreneurship. The company is preparing for a potential listing on the Hong Kong stock market, which could enhance its presence in the international capital market [2][3]. Group 1: Company Overview - Ruipai Pet was established in December 2012 with a registered capital of 100 million yuan, primarily owned by Zhongrui Huapu and individual shareholders [3]. - The company has undergone multiple financing rounds, raising a total of 2.147 billion yuan from investors including Mars China and Goldman Sachs [3][4]. - As of the first half of 2025, Ruipai Pet operates 548 pet hospitals, making it the second-largest pet medical service provider in China [19]. Group 2: Financial Performance - Ruipai Pet's revenue has shown consistent growth, with figures of 1.455 billion yuan in 2022, 1.585 billion yuan in 2023, and projected 1.758 billion yuan in 2024, alongside a revenue of 943.13 million yuan in the first half of 2025, reflecting an 8.52% year-on-year increase [19][20]. - The core business of diagnostic services has also seen growth, with revenues of 1.296 billion yuan in 2022 and projected 1.593 billion yuan in 2024 [19]. - The gross profit margin for Ruipai Pet has fluctuated, with a margin of 22.4% in 2022, 21.0% in 2023, and increasing to 24.8% in the first half of 2025 [27][28]. Group 3: Ownership and Control - Li Shoujun, the actual controller of Ruipai Pet, holds a 26.91% stake in the company through Zhongrui Huapu and Ruipu Biology [8]. - The company has seen various shareholders transfer their stakes, with significant transactions occurring in 2020 and 2022, indicating active management of equity [5][6]. Group 4: Operational Insights - Ruipai Pet's hospitals are primarily acquired, with 428 out of 548 hospitals being obtained through acquisitions [21]. - The company has a diverse range of services, including pet product sales and grooming services, although these contribute a smaller portion of total revenue compared to diagnostic services [19][23]. - The average revenue contribution per city center hospital is significantly higher than that of community hospitals, indicating a strategic focus on higher-margin facilities [21]. Group 5: Future Prospects - Ruipai Pet is preparing for a potential IPO, which could provide additional capital for expansion and enhance its market position [2][3]. - The company has maintained positive operating cash flow, with net inflows of 2.92 billion yuan in 2022 and 2.63 billion yuan in the first half of 2025 [29].

Investment Rating - The industry investment rating is "Positive" and is maintained [5] Core Viewpoints - The pig farming sector is expected to benefit from recent policies and market dynamics that promote capacity reduction, leading to a potential price turning point in Q2 2026, with long-term performance improvements anticipated for related stocks [3][43] - The structural growth trend in the post-cycle sector continues, with profits likely to gradually transmit downstream if the current round of pig capacity reduction proceeds smoothly, benefiting the animal health sector [3] - The planting chain shows a confirmed upward trend in grain prices, indicating favorable fundamentals for planting and seed industries, highlighting significant investment opportunities [3] - The pet food sector is experiencing growth and price increase logic, with continuous recognition of domestic brands and sustained growth of leading companies [3] Summary by Sections Pig Farming - The average price of live pigs as of December 31 was 12.76 yuan/kg, a week-on-week increase of 10.38%, while the average price of 15 kg piglets was 19.44 yuan/kg, up 2.21% week-on-week [12][51] - The supply side shows a widening price gap for fattened pigs, supporting price increases, while demand is boosted by consumption expectations during the New Year holiday [12][17] Poultry - The price of white feather broilers increased to 7.82 yuan/kg, up 6.39% week-on-week, and chick prices rose to 3.59 yuan/chick, up 1.7% week-on-week [17][51] - The supply of meat chickens has increased, leading to a more relaxed market supply, while demand has weakened due to some slaughterhouses reducing operations [17] Feed Sector - The prices of corn, wheat, and soybean meal have risen, with corn averaging 2351.57 yuan/ton, up 0.57% week-on-week, and soybean meal at 3172.29 yuan/ton, up 0.96% week-on-week [27][51] - Increased selling enthusiasm among farmers is noted, although the pace of supply remains slow [27] Major Agricultural Products - The domestic natural rubber futures price was 15605 yuan/ton as of December 31, down 0.29% week-on-week, with inventory levels increasing [38][51] - The current down cycle for sugar prices continues, with no significant recovery expected [39]

Core Viewpoint - The animal health sector experienced a slight decline of 0.05% on December 31, with Xianfeng Holdings leading the drop. The Shanghai Composite Index rose by 0.09%, while the Shenzhen Component Index fell by 0.58 [1] Group 1: Market Performance - The closing price of Xianfeng Holdings was 3.73, down by 2.61%, with a trading volume of 182,700 shares and a transaction amount of 68.47 million [2] - The animal health sector's main stocks showed mixed performance, with *ST Lvkang rising by 2.46% to 33.71, while several others, including Xianfeng Holdings and Ruipu Bio, saw declines [1][2] - The total trading volume in the animal health sector was significant, with major stocks like Ruipu Bio and Xianfeng Holdings contributing to the overall market activity [2] Group 2: Capital Flow - The animal health sector saw a net outflow of 45.26 million from institutional investors, while retail investors contributed a net inflow of 39.94 million [2] - The capital flow data indicates that retail investors were more active in the market, with a notable net inflow compared to the outflow from institutional investors [2] - Specific stocks like Huisheng Bio and *ST Lvkang had varying levels of net inflow and outflow from different investor categories, reflecting diverse investor sentiment [3]

Investment Rating - The report maintains an "Overweight" rating for the agriculture, forestry, animal husbandry, and fishery industry [1][42] Core Views - The SW agriculture, forestry, animal husbandry, and fishery industry slightly underperformed the CSI 300 index, with an increase of 1.55% from December 12 to December 25, 2025, lagging behind the index by approximately 0.43 percentage points [11][14] - All sub-sectors recorded positive returns during the same period, with notable increases in agricultural product processing (3.04%), animal health (2.95%), planting (2.28%), fishery (1.56%), breeding (0.81%), and feed (0.29%) [14][15] - The overall price-to-book (PB) ratio for the industry is approximately 2.79 times, indicating a slight recovery in valuation, which remains at a historical low level, around the 62.7 percentile since 2006 [18][24] Industry Important Data - **Pig Farming**: The average price of external three-way cross pigs increased from 11.45 CNY/kg to 11.59 CNY/kg during the reporting period. The cost of corn and soybean meal has slightly decreased, with corn priced at 2338.04 CNY/ton and soybean meal at 3102 CNY/ton as of December 25, 2025 [22][24] - **Profitability**: As of December 26, 2025, the profit for self-bred pigs was -130.11 CNY/head, and for purchased piglets, it was -162.8 CNY/head, showing a reduction in losses compared to the previous two weeks [27] - **Poultry Farming**: The average price of broiler chicks was 3.59 CNY/chick, showing a slight increase, while the average price for white feather broilers was 7.82 CNY/kg, with profitability improving to 0.89 CNY/chick [29][33] Industry Insights - The report emphasizes the potential for a rebound in pig prices as the seasonal consumption peak approaches, with a focus on the high inventory of breeding sows and the opportunities for leading pig farming companies [42][43] - In poultry farming, the report highlights the recovery in white feather broiler prices and the improvement in profitability, suggesting a positive outlook for leading poultry companies [42][43] - The report also notes growth potential in the domestic pet market and the expected increase in export volumes, recommending attention to promising domestic leaders in this sector [42][43]

证券代码：300119 证券简称：瑞普生物 公告编号：2025-100 瑞普生物股份有限公司 关于取得新兽药注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 根据《兽药管理条例》和《兽药注册办法》的规定，瑞普生物股份有限公司 （以下简称"公司""瑞普生物"）及下属分子公司天津瑞普生物技术股份有限 公司空港经济区分公司、瑞普（保定）生物药业有限公司 2 款新兽药产品近日获 农业农村部批准，详情如下： 原体流行菌株，能够显著减少免疫猪群肺炎病变损伤；副猪嗜血杆菌抗原覆盖主 要流行血清型 4 型、5 型菌株，可有效降低或阻断相应菌株感染。该产品采用无 血清全悬浮细胞培养、细菌高密度发酵和高效的浓缩纯化等先进技术，实现制苗 抗原的精纯制备；开发相对效力标准和菌体蛋白浓度制苗标准，实现工艺稳定、 均一可控；搭配兼顾多种抗原组合安全性和免疫效果的水性佐剂，显著降低副反 应发生率。该疫苗免疫后 4 周可产生免疫力，免疫持续期可达 5 个月，实现"一 针三防"，大幅简化临床免疫程序，助力养殖场提升免疫效率、节省人力成本、 减少猪群临床免疫应激。 该产品的成功获批 ...

Group 1 - The animal vaccine sector experienced a decline of 0.47%, ranking among the top losers in concept sectors, with notable declines from companies like BioShares, Luo Niu Shan, and Tian Kang Bio [1] - Among the stocks in the animal vaccine sector, 10 stocks saw price increases, with Hengtong Co., Hai Zheng Pharmaceutical, and Hai Li Bio leading the gains at 3.67%, 0.69%, and 0.48% respectively [1] - The main capital outflow from the animal vaccine sector today was 87 million yuan, with 14 stocks experiencing net outflows, led by Luo Niu Shan with a net outflow of 95.06 million yuan [2] Group 2 - The top net inflow stocks in the animal vaccine sector included BioShares, Da Bei Nong, and Zhong Mu Co., with net inflows of 46.84 million yuan, 6.50 million yuan, and 3.83 million yuan respectively [2][3] - The capital outflow leaderboard for the animal vaccine sector included Luo Niu Shan, Hengtong Co., and Rui Pu Bio, with respective outflows of 95.06 million yuan, 11.49 million yuan, and 7.66 million yuan [2][3] - The trading activity showed that Luo Niu Shan had a turnover rate of 16.52%, while other companies like Hengtong Co. and Tian Kang Bio had turnover rates of 3.51% and 1.98% respectively [2][3]

Core Insights - The animal health sector experienced a slight increase of 0.42% on December 19, with Huisheng Biological leading the gains [1] - The Shanghai Composite Index closed at 3890.45, up 0.36%, while the Shenzhen Component Index closed at 13140.22, up 0.66% [1] Stock Performance - Huisheng Biological (300871) closed at 20.75, with a rise of 2.47% and a trading volume of 45,200 shares, amounting to a transaction value of 92.96 million yuan [1] - Other notable performers included: - Qudongli (920275) at 9.27, up 2.43% [1] - Shenlian Biological (688098) at 9.01, up 2.15% [1] - Xianfeng Holdings (002141) at 3.74, up 1.91% [1] - Ruipu Biological (300119) at 19.60, up 1.87% [1] Capital Flow - The animal health sector saw a net outflow of 129 million yuan from institutional investors, while retail investors contributed a net inflow of 157 million yuan [2][3] - The detailed capital flow for selected stocks showed: - Xianfeng Holdings (002141) had a net inflow of 6.89 million yuan from institutional investors [3] - Ruipu Biological (300119) experienced a net outflow of 15.98 million yuan from institutional investors but a net inflow of 11.27 million yuan from retail investors [3] - Qudongli (920275) had a net inflow of 2.22 million yuan from retail investors [3]

Core Insights - The core viewpoint of the articles highlights the significant growth and strategic positioning of the company, Ruipu Biological, in the animal health industry, aiming to become a leader in both China and globally [2][3]. Group 1: Financial Performance - In 2024, the company is projected to achieve revenue exceeding 3 billion yuan, with a 14% year-on-year growth in the first three quarters of 2025, reaching 2.5 billion yuan and a net profit of 360 million yuan, marking a 46% increase [2]. - The company completed a targeted issuance of 1.336 billion yuan in 2021 to support its industrial chain upgrade [2]. Group 2: Industry Positioning - Ruipu Biological is the first publicly listed company in the A-share market focused on veterinary medicine, holding the largest market share in the domestic industry [2]. - The company has established a comprehensive industrial chain covering 12 large-scale production bases across 8 provinces, with products exported to over 50 countries and regions [2]. Group 3: Research and Development - The company invests over 200 million yuan annually in R&D, accounting for 7.76% of its revenue, and has built 6 national-level innovation platforms [2]. - As of now, the company has obtained 121 new veterinary drug registration certificates and 330 authorized patents, with a significant milestone being the clinical approval of the world's first mRNA vaccine for food animals in 2025 [2]. Group 4: Future Strategy - The company aims to become the number one in China's animal health industry and among the top five globally, focusing on synthetic biology, mRNA vaccines, and genetic engineering [3]. - Plans include expanding global reach, particularly in the "Belt and Road" markets, and creating a comprehensive ecosystem encompassing vaccines, pharmaceuticals, health products, and medical services [3].

Core Viewpoint - RuiPu Bio, the first A-share listed company focused on veterinary medicine, aims for significant growth during the "14th Five-Year Plan" period, leveraging capital market operations and strategic investments in biomanufacturing [1][2] Financial Performance - In 2024, the company expects revenue to exceed 3 billion yuan, with a 14% year-on-year growth in the first three quarters of 2025, achieving 2.5 billion yuan in revenue and a net profit of 360 million yuan, marking a 46% increase [1] - The pet supply chain revenue reached 633 million yuan in 2024, reflecting a 37.66% year-on-year growth [1] Industry Positioning - RuiPu Bio holds the largest market share in the domestic veterinary medicine sector and has established a comprehensive industry chain covering 12 large-scale production bases across 8 provinces [1] - The company exports products to over 50 countries and regions worldwide [1] Research and Development - The company invests over 200 million yuan annually in R&D, accounting for 7.76% of its revenue, and has established 6 national-level innovation platforms [2] - RuiPu Bio has received 121 new veterinary drug registration certificates and holds 330 authorized patents [2] - In 2025, the company is set to receive clinical approval for the world's first mRNA vaccine for food animals, targeting porcine epidemic diarrhea virus [2] Strategic Goals - The company aims to become the leading player in China's animal health industry and rank among the top five globally, focusing on synthetic biology, mRNA vaccines, and genetic engineering [2] - RuiPu Bio plans to expand its global footprint, particularly in the "Belt and Road" markets, and to innovate within the "vaccine-drug-healthcare-medical service" ecosystem [2]